<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Chase Norton | Activity</title>
	<link>https://www.catswannabecats.com/members/woundfelony93/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/woundfelony93/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Chase Norton.</description>
	<lastBuildDate>Wed, 08 Jul 2026 13:16:13 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">46d5e54e4213514de72677eea1f92bf8</guid>
				<title>Chase Norton posted an update: After multikinase inhibitor approval, patients with small [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/12530/</link>
				<pubDate>Sun, 01 Jun 2025 11:01:32 -0400</pubDate>

									<content:encoded><![CDATA[<p>After multikinase inhibitor approval, patients with small tumors, extrathyroidal extension, positive lymph nodes, or metastases were more likely to receive systemic therapy (P less then .05). The 5-year overall survival between pre and postmultikinase inhibitor groups, for those who received systemic therapy (n = 288), was similar (P = .58), even&hellip;<span class="activity-read-more" id="activity-read-more-12530"><a href="https://www.catswannabecats.com/activity/p/12530/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a4c7e47de428667042151e28c2416005</guid>
				<title>Chase Norton posted an update: After multikinase inhibitor approval, patients with small [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/12472/</link>
				<pubDate>Sun, 01 Jun 2025 10:44:08 -0400</pubDate>

									<content:encoded><![CDATA[<p>After multikinase inhibitor approval, patients with small tumors, extrathyroidal extension, positive lymph nodes, or metastases were more likely to receive systemic therapy (P less then .05). The 5-year overall survival between pre and postmultikinase inhibitor groups, for those who received systemic therapy (n = 288), was similar (P = .58), even&hellip;<span class="activity-read-more" id="activity-read-more-12472"><a href="https://www.catswannabecats.com/activity/p/12472/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7dcb8fbc5e2637cd5c24b67cc17bb532</guid>
				<title>Chase Norton posted an update: Atopic dermatitis (AD) is a chronic relapsing inflammatory [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/2180/</link>
				<pubDate>Sat, 31 May 2025 07:58:39 -0400</pubDate>

									<content:encoded><![CDATA[<p>Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, associated with impaired skin barrier function and an atopic background. Various complicating factors, such as irritants, aeroallergens, food, microbial organisms, contact allergens, sweat, and scratching can induce the development of AD symptoms. <a href="https://www.selleckchem.com/products/cerdulatinib.html" rel="nofollow ugc">buy Cerdulatinib</a> Irritants,&hellip;<span class="activity-read-more" id="activity-read-more-2180"><a href="https://www.catswannabecats.com/activity/p/2180/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">391f8cb7ed5278245f37d4c26cfd025c</guid>
				<title>Chase Norton became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/1921/</link>
				<pubDate>Sat, 31 May 2025 07:40:06 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>